Physiologically based pharmacokinetic modelling to predict potential drug–drug interactions of dersimelagon (MT‐7117)
Overall, PBPK modelling results indicate that the simulated changes in plasma exposure of atorvastatin and rosuvastatin following coadministration with dersimelagon 100 or 200 mg are not clinically significant, but caution and appropriate clinical monitoring should be recommended.
Authors
- Yukiko Murata (ORCID: https://orcid.org/0000-0003-1108-4935)
- H. Shimizu (ORCID: https://orcid.org/0000-0002-4208-9790)
- Akihito Ogasawara (ORCID: https://orcid.org/0000-0002-1652-1711)
- Koki Kojima
Institutions
- Mitsubishi Group (Japan) (JP)
- Mitsubishi Tanabe Pharma Corporation
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1111/bcp.16271
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Mitsubishi Tanabe Pharma Corporation